The Acinetobacter pneumonia therapeutics market consists of drugs and therapies used for treating pneumonia caused by Acinetobacter bacteria. Acinetobacter pneumonia is a hospital-acquired infection most commonly observed in intensive care units. The increasing prevalence of multidrug-resistant Acinetobacter strains has made treatment challenging. Major drugs used include carbapenems, aminoglycosides, polymyxins, and tetracyclines. \
The global acinetobacter pneumonia therapeutics market size is expected to reach US$ 899.1 Mn by 2030, from US$ 614.6 Mn in 2023, exhibiting a CAGR of 5.6% during the forecast period.
Key players operating in the Acinetobacter pneumonia therapeutics market are Merck & Co., Pfizer Inc., Tetraphase Pharmaceuticals, BioVersys GmbH, Achaogen Inc., LegoChem Biosciences Inc. The market sees significant opportunities due to rising R&D activities focused on developing novel drug formulations. Market leaders are investing heavily in clinical trials to evaluate new drug candidates. Furthermore, the increasing global burden of nosocomial infections is prompting pharmaceutical companies to expand their product portfolios catering to hospital-acquired pneumonia.
The rising incidence of hospital-acquired infections is a major Acinetobacter Pneumonia Therapeutics Market Demand driver. According to the Centers for Disease Control and Prevention, over 7,00,000 patients in the US acquire an HAI each year leading to around 75,000 deaths annually. The high prevalence of multidrug-resistant strains of Acinetobacter further increases morbidity and mortality. Moreover, the growing elderly population vulnerable to nosocomial pneumonia and a large patient pool in developing markets will support the market growth during the forecast period.
PEST Analysis
Political: Government policies and regulations play a crucial role in therapeutics development and approval processes. Changes in healthcare reforms and medical guidelines may impact R&D investment decisions.
Economic: Global recession can negatively impact the healthcare expenditure of individuals as well as governments. This may affect the sales volume of therapeutics in certain countries or regions.
Social: Growing elderly population suffering from chronic conditions increases the risk of pneumonia. Raising awareness about disease prevention and treatment-seeking behavior can boost the demand for anti-infectives.
Technological: Advancements in drug delivery systems and genome-based characterization of pathogens enable development of targeted drugs with improved efficacy and safety profiles. Emerging diagnostic technologies facilitate early detection and management of infection cases.
Geographical regions of concentration
North America dominates the market in terms of revenue, owing to the strong foothold of leading manufacturers and availability of advanced healthcare facilities. The United States accounts for a major portion of the regional market share. Favorable reimbursement policies and high per capita healthcare expenditure contribute to the large market size.
Fastest growing region
Asia Pacific region is poised to witness the fastest growth over the forecast period. Rapidly developing economies such as India and China are witnessing rising incidence of hospital-acquired infections. Increasing healthcare spending, growing medical tourism, and availability of generic drugs are some factors driving the regional market. Rising awareness about pneumonia and initiatives to expand healthcare infrastructure also support market expansion in Asia Pacific.
Get this Report in Japanese Language:
Get this Report in Korean Language:
About Author:
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)
Comments
0 comment